Upstream Bioprocessing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Upstream Bioprocessing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The upstream bioprocessing market is expected to register a CAGR of 5.5% over the forecast period.

The outbreak of the COVID-19 pandemic has pushed the pharmaceutical industry into action, with a race to develop both therapeutic and preventive drugs. Exponentially increasing cases of the coronavirus worldwide are leading to the need for the development of novel treatments, with several clinical trials underway. Meanwhile, the manufacturers of drugs were highly focused on developing vaccines and drugs, which can also be applied in the diagnosis and treatment of COVID-19, thereby increasing the rate of upstream bioprocessing to a great extent. For instance, according to the journal published by the Eppendorf in April 2021, the COVID-19 pandemic starting in 2020 underlined the strong need for the efficient development of new upstream bioprocesses. The fast and reliable upstream bioprocessing to scale up to clinical production volumes is the key to the efficient development of new vaccinations. Furthermore, according to the journal published by BioProcess International in September 2021, the single-use bioprocessing technologies has emerged as the dominating procedure in the pre-commercial manufacturing space. However, shortage of single-use bioprocessors during COVID-19 has hindered the market growth initially. For instance, according to the journal published by the BioProcess International in September 2021, Biopharma faced delays in obtaining single-use systems due to the disruption caused by the COVID-19 pandemic and increasing demand of the system. Therefore, the market witnessed a moderate growth during the pandemic.

The rising adoption of single-use upstream bioprocessing, commercial success and rising demand for biotherapeutics, and increasing research activities are the major factors driving the market growth over the forecast period. For instance, as per the journal publishec by the BioPharm International in April 2021, developing and scaling up manufacturing operations and analytical testing capabilities is demanding the need for developing advanced upsteam bioprocessing technologies. Upstream bioprocessing is very important in research activities for the development of biosimilars, therapeutic peptide, and monoclonal antibodies. Moreover, the upstream bioprocessing is contamination-free, safe, efficient production which aids the demand of these process further propels the market. Furthermore, the growing awareness and implementation of the Process Analytical Technology (PAT) strategy to monitor, analyze and optimize cell culture production process through various parameters such as real-time nutrient analysis and inline monitoring of cell density also helps in increasing the market. This technology helps in critical quality attributes of the upstream bioprocessing and further improves the productivity of the process and boost the market. Therefore, owing to such factors considerable market growth is anticipated over the forecast period.

However, operational challenges pertaining to upstream bioprocessing is expected to restraint the market growth over the forecast period.

Key Market TrendsBioreactors/Fermenters is Expected to Witness Growth Over the Forecast Period

Bioreactors/Fermenters in upstream bioprocessing are expected to witness healthy growth in the future due to the wide application in small and large bioproduction. A bioreactor/fermenters are an indispensable part of any bioprocess, whether the process degrades pollutants or produces substances such as food, feed, chemicals and drugs, and tissues and organs for biomedical use. A bioreactor/fermentor provides an ideal environment for the cells to proliferate. It also helps to maintain accurate pH, temperature, and sufficient gas supply and also adds nutrients for successful maintenance of growth.

The increasing R&D expenditure, research activities globally, and several advantages related to bioreactors/ fermenters are the major factors driving the segment growth over the forecast period. For instance, in March 2021, the United States Pharmacopeia (USP) and Phlow Corp. collaborated to build a new laboratory that will develop test methods and standards for continuous manufacturing. This establishment is focused on product development, tech transfer, and drug application filings using continuous manufacturing to foster wider adoption of continuous manufacturing by generic drugs and other pharmaceutical manufacturers. Since, bioreactors/fermenters is one of the primary requirement for reseach activities, therefore this may propel the segment growth.

Therefore, owing to the above mentioned factors the segment is anticipated to witness considerable growth over the forecast period.

North America is Expected to Dominate the Upstream Bioprocessing Market Over the Forecast Period

North America is expected to dominate the overall upstream bioprocessing market, over the forecast period. The growth is due to the factors such as increasing research and development spending, the presence of largescale manufacturing units, the growing popularity of disposables, and increasing healthcare expenditure, and the presence of a well-established healthcare infrastructure. For instance, in March 2020, the government of Canada announced CAD 275.0 million for the research and development activities related to antivirals, diagnostics, vaccines, and clinical trials for COVID-19. Furthermore, in April 2020, Moderna Inc. received USD 483 million from the government of the United States for the development of the vaccine against COVID-19. Upstream bioprocessing is one of the essential steps for the development of vaccines, drug development, and clinical trials, thus such a scenario is expected to boost market growth.

Key product launches, high concentration of market players or manufacturer's presence, and acquisition & partnerships among major players, and initiatives related to upstream bioprocessing by the players in the United States are some of the factors driving the growth of the upstream bioprocessing market in the country. For instance, in November 2021, Bionova opened a USD 25.0 million single-use plants in Fremont, California. The plant is equipped with a 1,000 L Cytiva XDR upstream train. In addition, the company is also planning to add a 2,000 L Cytiva system by Q3'2022.

Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the North America Region.

Competitive Landscape

The upstream bioprocessing market is moderately competitive and consists of several major players. Some of the key operating players include Thermo Fisher Scientific Inc., Danaher Corporation (Cytvia), Corning, Inc., Merck KGaA, Eppendorf AG, Sartorius AG, Boehringer Ingelheim GmbH, Danaher Corporation, Applikon Biotechnology, and CellGenix GmbH.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.